SCHEMBL5497568

SCHEMBL5497568

CCCCCc1ccc(O)c(C(=O)Nc2ccccc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT8 Q9H7Z6 2/20 0.64
ALOX15 P16050 4/20 0.63
TRPV1 Q8NER1 1/20 0.59
TMPRSS4 Q9NRS4 1/20 0.55
PPARA Q07869 1/20 0.53
KDM4E B2RXH2 2/20 0.53
MEN1 O00255 2/20 0.53
HPGD P15428 2/20 0.53
HTT P42858 2/20 0.53
KMT2A Q03164 2/20 0.53
NPC1 O15118 1/20 0.53
GAA P10253 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51
HSD17B10 Q99714 1/20 0.51
HDAC3 O15379 1/20 0.50
EGFR P00533 1/20 0.50
HDAC4 P56524 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9826537 0.83 ALOX15 (0.72) ALOX15TRPV1KDM4EMEN1HPGD
SCHEMBL10606316 0.82 MAPT (0.56) KAT8ALOX15TMPRSS4MEN1HTT
SCHEMBL24539597 0.81 TRPV1 (0.58) ALOX15TRPV1PPARAKDM4EMEN1
SCHEMBL21332089 0.81 KAT8 (0.71) KAT8TRPV1PPARAKDM4EMEN1
Hydrochloric Acid SCHEMBL10386190 0.80 ALOX15 (0.55) KAT8ALOX15
SCHEMBL1079224 0.80 KAT8 (0.97) KAT8PPARAEGFR
SCHEMBL11517335 0.80 KAT8 (0.74) KAT8ALOX15PPARAKDM4ELMNA
SCHEMBL10607741 0.80 P2RX1 (0.63) TMPRSS4MEN1HTTKMT2ASMN1; SMN2
SCHEMBL6283982 0.79 HNF4A (0.67) ALOX15TMPRSS4KDM4EMEN1HPGD
SCHEMBL8531761 0.79 KAT8 (0.77) KAT8TRPV1PPARAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0628302-A2 Oral composition containing salicylanilide antibacterial agent Colgate-Palmolive Company (US) 1994-12-14 EP claimed
US-5275805-A Inhibitors of plaque in mouths with mixtures of salicylanilide and nonionic surfactants COLGATE-PALMOLIVE CO. 1994-01-04 US claimed
EP-0038191-B1 5-ACYLSALICYLANILIDES DERIVATIVES AND METHOD FOR INHIBITING THE GROWTH OF MICROORGANISMS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1984-07-25 EP claimed
EP-1328507-B1 NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTIINFLAMMATORY AGENTS UNIV NEW YORK STATE RES FOUND (US) 2007-03-14 EP disclosed
EP-1328507-A1 NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTIINFLAMMATORY AGENTS The Research Foundation Of State University of New York (US) 2003-07-23 EP disclosed
US-6407288-B1 AS ANTIBACTERIAL AGAINST GRAM NEGATIVE AND GRAM POSITIVE BACTERIA AND AS ANTIINFLAMMATORY AGENTS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2002-06-18 US disclosed
US-20020065322-A1 NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTIINFLAMMATORY AGENTS RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE 2002-05-30 US disclosed
WO-2002028819-A1 NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTIINFLAMMATORY AGENTS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2002-04-11 WO disclosed
EP-0628302-A2 Oral composition containing salicylanilide antibacterial agent Colgate-Palmolive Company (US) 1994-12-14 EP disclosed
US-5275805-A Inhibitors of plaque in mouths with mixtures of salicylanilide and nonionic surfactants COLGATE-PALMOLIVE CO. 1994-01-04 US disclosed
EP-0221211-B1 USE OF SECONDARY AMIDE COMPOUNDS FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF DERMATOLOGICAL INFLAMMATION UNILEVER PLC (GB) 1989-01-11 EP disclosed
EP-0221211-A1 Use of secondary amide compounds for the manufacture of medicaments for the treatment of dermatological inflammation UNILEVER PLC (GB) 1987-05-13 EP disclosed
US-4560549-A TOPICAL AND SYSTEMICAL; HUMANS ANIMALS; MICROBIOCIDES LEVER BROTHERS COMPANY (US) 1985-12-24 US disclosed
EP-0038191-B1 5-ACYLSALICYLANILIDES DERIVATIVES AND METHOD FOR INHIBITING THE GROWTH OF MICROORGANISMS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1984-07-25 EP disclosed
EP-0038191-B1 5-ACYLSALICYLANILIDES DERIVATIVES AND METHOD FOR INHIBITING THE GROWTH OF MICROORGANISMS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1984-07-25 EP disclosed
EP-0038191-A1 5-Acylsalicylanilides derivatives and method for inhibiting the growth of microorganisms THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1981-10-21 EP disclosed
EP-0038191-A1 5-Acylsalicylanilides derivatives and method for inhibiting the growth of microorganisms THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1981-10-21 EP disclosed
EP-0038191-A1 5-Acylsalicylanilides derivatives and method for inhibiting the growth of microorganisms THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1981-10-21 EP disclosed
US-4287191-A Novel salicylanilides and microbiocidal compositions and uses thereof THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1981-09-01 US disclosed
US-4287191-A Novel salicylanilides and microbiocidal compositions and uses thereof THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1981-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065322-A1 NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTIINFLAMMATORY AGENTS PTGES3, FPR3, PTGS1 KAT8 3258/4885ALOX15 31/4885TRPV1 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.